位置:首页 > 蛋白库 > PGH1_BOVIN
PGH1_BOVIN
ID   PGH1_BOVIN              Reviewed;         600 AA.
AC   O62664; A7YWD4;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 2.
DT   03-AUG-2022, entry version 164.
DE   RecName: Full=Prostaglandin G/H synthase 1 {ECO:0000305};
DE            EC=1.14.99.1 {ECO:0000250|UniProtKB:P23219};
DE   AltName: Full=Cyclooxygenase-1;
DE            Short=COX-1;
DE   AltName: Full=Prostaglandin H2 synthase 1;
DE            Short=PGH synthase 1;
DE            Short=PGHS-1;
DE            Short=PHS 1;
DE   AltName: Full=Prostaglandin-endoperoxide synthase 1;
DE   Flags: Precursor;
GN   Name=PTGS1; Synonyms=COX-1, COX1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Hereford; TISSUE=Ascending colon;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 121-379.
RX   PubMed=9348208; DOI=10.1210/endo.138.11.5527;
RA   Asselin E., Drolet P., Fortier M.A.;
RT   "Cellular mechanisms involved during oxytocin-induced prostaglandin F2alpha
RT   production in endometrial epithelial cells in vitro: role of
RT   cyclooxygenase-2.";
RL   Endocrinology 138:4798-4805(1997).
CC   -!- FUNCTION: Dual cyclooxygenase and peroxidase in the biosynthesis
CC       pathway of prostanoids, a class of C20 oxylipins mainly derived from
CC       arachidonate, with a particular role in the inflammatory response. The
CC       cyclooxygenase activity oxygenates arachidonate (AA, C20:4(n-6)) to the
CC       hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase
CC       activity reduces PGG2 to the hydroxy endoperoxide PGH2, the precursor
CC       of all 2-series prostaglandins and thromboxanes. This complex
CC       transformation is initiated by abstraction of hydrogen at carbon 13
CC       (with S-stereochemistry), followed by insertion of molecular O2 to form
CC       the endoperoxide bridge between carbon 9 and 11 that defines
CC       prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase
CC       activity) yields a hydroperoxy group in PGG2 that is then reduced to
CC       PGH2 by two electrons. Involved in the constitutive production of
CC       prostanoids in particular in the stomach and platelets. In gastric
CC       epithelial cells, it is a key step in the generation of prostaglandins,
CC       such as prostaglandin E2 (PGE2), which plays an important role in
CC       cytoprotection. In platelets, it is involved in the generation of
CC       thromboxane A2 (TXA2), which promotes platelet activation and
CC       aggregation, vasoconstriction and proliferation of vascular smooth
CC       muscle cells. {ECO:0000250|UniProtKB:P23219}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + 2 O2 = A + H2O +
CC         prostaglandin H2; Xref=Rhea:RHEA:23728, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:57405; EC=1.14.99.1;
CC         Evidence={ECO:0000250|UniProtKB:P23219};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:23729;
CC         Evidence={ECO:0000250|UniProtKB:P23219};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + 2 O2 = prostaglandin G2;
CC         Xref=Rhea:RHEA:42596, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:82629; Evidence={ECO:0000250|UniProtKB:P23219};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42597;
CC         Evidence={ECO:0000250|UniProtKB:P23219};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=AH2 + prostaglandin G2 = A + H2O + prostaglandin H2;
CC         Xref=Rhea:RHEA:42600, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:57405, ChEBI:CHEBI:82629;
CC         Evidence={ECO:0000250|UniProtKB:P23219};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42601;
CC         Evidence={ECO:0000250|UniProtKB:P23219};
CC   -!- COFACTOR:
CC       Name=heme b; Xref=ChEBI:CHEBI:60344; Evidence={ECO:0000250};
CC       Note=Binds 1 heme b (iron(II)-protoporphyrin IX) group per subunit.
CC       {ECO:0000250};
CC   -!- ACTIVITY REGULATION: The cyclooxygenase activity is inhibited by
CC       nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen,
CC       flurbiprofen, ketoprofen, naproxen, flurbiprofen, anirolac, fenclofenac
CC       and diclofenac. {ECO:0000250|UniProtKB:P23219}.
CC   -!- PATHWAY: Lipid metabolism; prostaglandin biosynthesis.
CC       {ECO:0000250|UniProtKB:P23219}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Microsome membrane; Peripheral membrane protein.
CC       Endoplasmic reticulum membrane; Peripheral membrane protein.
CC   -!- MISCELLANEOUS: The conversion of arachidonate to prostaglandin H2 is a
CC       2 step reaction: a cyclooxygenase (COX) reaction which converts
CC       arachidonate to prostaglandin G2 (PGG2) and a peroxidase reaction in
CC       which PGG2 is reduced to prostaglandin H2 (PGH2). The cyclooxygenase
CC       reaction occurs in a hydrophobic channel in the core of the enzyme. The
CC       peroxidase reaction occurs at a heme-containing active site located
CC       near the protein surface. The nonsteroidal anti-inflammatory drugs
CC       (NSAIDs) binding site corresponds to the cyclooxygenase active site.
CC   -!- MISCELLANEOUS: Conversion of arachidonate to prostaglandin H2 is
CC       mediated by 2 different isozymes: the constitutive PTGS1 and the
CC       inducible PTGS2. PTGS1 is expressed constitutively and generally
CC       produces prostanoids acutely in response to hormonal stimuli to fine-
CC       tune physiological processes requiring instantaneous, continuous
CC       regulation (e.g. hemostasis). PTGS2 is inducible and typically produces
CC       prostanoids that mediate responses to physiological stresses such as
CC       infection and inflammation.
CC   -!- MISCELLANEOUS: PTGS1 and PTGS2 are the targets of nonsteroidal anti-
CC       inflammatory drugs (NSAIDs) including aspirin and ibuprofen. Aspirin is
CC       able to produce an irreversible inactivation of the enzyme through a
CC       serine acetylation. Inhibition of the PGHSs with NSAIDs acutely reduces
CC       inflammation, pain, and fever, and long-term use of these drugs reduces
CC       fatal thrombotic events, as well as the development of colon cancer and
CC       Alzheimer's disease. PTGS2 is the principal isozyme responsible for
CC       production of inflammatory prostaglandins. New generation PTGSs
CC       inhibitors strive to be selective for PTGS2, to avoid side effects such
CC       as gastrointestinal complications and ulceration.
CC   -!- SIMILARITY: Belongs to the prostaglandin G/H synthase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC134517; AAI34518.1; -; mRNA.
DR   EMBL; AF004943; AAC05591.1; -; mRNA.
DR   RefSeq; NP_001098793.1; NM_001105323.1.
DR   AlphaFoldDB; O62664; -.
DR   SMR; O62664; -.
DR   STRING; 9913.ENSBTAP00000008833; -.
DR   BindingDB; O62664; -.
DR   ChEMBL; CHEMBL2860; -.
DR   DrugCentral; O62664; -.
DR   PeroxiBase; 3332; BtPGHS01.
DR   PaxDb; O62664; -.
DR   PRIDE; O62664; -.
DR   GeneID; 282022; -.
DR   KEGG; bta:282022; -.
DR   CTD; 5742; -.
DR   eggNOG; KOG2408; Eukaryota.
DR   HOGENOM; CLU_022428_0_0_1; -.
DR   InParanoid; O62664; -.
DR   OrthoDB; 324380at2759; -.
DR   TreeFam; TF329675; -.
DR   BRENDA; 1.14.99.1; 908.
DR   UniPathway; UPA00662; -.
DR   PRO; PR:O62664; -.
DR   Proteomes; UP000009136; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016702; F:oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen; IBA:GO_Central.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004666; F:prostaglandin-endoperoxide synthase activity; IBA:GO_Central.
DR   GO; GO:0019371; P:cyclooxygenase pathway; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IEA:InterPro.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:InterPro.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:InterPro.
DR   Gene3D; 1.10.640.10; -; 1.
DR   InterPro; IPR029580; COX-1.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR019791; Haem_peroxidase_animal.
DR   InterPro; IPR010255; Haem_peroxidase_sf.
DR   InterPro; IPR037120; Haem_peroxidase_sf_animal.
DR   PANTHER; PTHR11903:SF6; PTHR11903:SF6; 1.
DR   Pfam; PF03098; An_peroxidase; 1.
DR   PRINTS; PR00457; ANPEROXIDASE.
DR   SUPFAM; SSF48113; SSF48113; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50292; PEROXIDASE_3; 1.
PE   2: Evidence at transcript level;
KW   Dioxygenase; Disulfide bond; EGF-like domain; Endoplasmic reticulum;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Glycoprotein; Heme; Iron;
KW   Lipid biosynthesis; Lipid metabolism; Membrane; Metal-binding; Microsome;
KW   Oxidoreductase; Peroxidase; Prostaglandin biosynthesis;
KW   Prostaglandin metabolism; Reference proteome; Signal.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..600
FT                   /note="Prostaglandin G/H synthase 1"
FT                   /id="PRO_0000163113"
FT   DOMAIN          32..70
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   ACT_SITE        207
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00298"
FT   ACT_SITE        385
FT                   /note="For cyclooxygenase activity"
FT                   /evidence="ECO:0000250"
FT   BINDING         388
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00298"
FT   SITE            530
FT                   /note="Aspirin-acetylated serine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        68
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        104
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        144
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        410
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        36..47
FT                   /evidence="ECO:0000250"
FT   DISULFID        37..159
FT                   /evidence="ECO:0000250"
FT   DISULFID        41..57
FT                   /evidence="ECO:0000250"
FT   DISULFID        59..69
FT                   /evidence="ECO:0000250"
FT   DISULFID        569..575
FT                   /evidence="ECO:0000250"
FT   CONFLICT        229
FT                   /note="D -> G (in Ref. 2; AAC05591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        241
FT                   /note="Q -> R (in Ref. 2; AAC05591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        263
FT                   /note="P -> Q (in Ref. 2; AAC05591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        320
FT                   /note="H -> Q (in Ref. 2; AAC05591)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   600 AA;  68805 MW;  0B43E65DA9E2A2E9 CRC64;
     MSRQGISLRF PLLLLLLSPS PVLPADPGAP APVNPCCYYP CQHQGICVRF GLDRYQCDCT
     RTGYYGPNCT IPEIWTWLRT TLRPSPSFVH FLLTHGRWLW DFVNATFIRD KLMRLVLTVR
     SNLIPSPPTY NVAHDYISWE SFSNVSYYTR ILPSVPRDCP TPMGTKGKKQ LPDAEFLSRR
     FLLRRKFIPD PQGTNLMFAF FAQHFTHQFF KTSGKMGPGF TKALGHGVDL GHIYGDNLER
     QYQLRLFKDG KLKYQMLNGE VYPPSVEEAP VLMHYPRGIP PQSQMAVGQE VFGLLPGLMV
     YATIWLREHN RVCDLLKAEH PTWGDEQLFQ TARLILIGET IKIVIEEYVQ QLSGYFLQLK
     FDPELLFGAQ FQYRNRIAME FNQLYHWHPL MPDSFRVGPQ DYSYEQFLFN TSMLVDYGVE
     ALVDAFSRQP AGRIGGGRNI DHHILHVAVD VIKESRELRL QPFNEYRKRF GMKPYTSFQE
     LTGEKEMAAE LEELYGDIDA LEFYPGLLLE KCHPNSIFGE SMIEMGAPFS LKGLLGNPIC
     SPEYWKASTF GGDVGFNLVK TATLKKLVCL NTKTCPYVSF HVPDPHREDR PGVERPPTEL
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024